Table 1.
Differential metabolic pathways (CT vs. LPS2). The results of enriched compounds after screening and metabolic metabolic pathway enrichment analysis (MPEA) between CT and LPS2 groups are summarized in this table.
| Total in pathway | Expected | Hits | Raw P | ′ − log(p) | Holm P | FDR | Impact | Enriched compounds | |
|---|---|---|---|---|---|---|---|---|---|
| Arginine and proline metabolism | 44 | 0.65906 | 5 | 0.000338 | 7.9912 | 0.027413 | 0.027413 | 0.18368 | Citrulline Fumaric acid L-Arginine L-Proline Urea |
| Aminoacyl-tRNA biosynthesis | 67 | 1.0036 | 5 | 0.002405 | 6.0301 | 0.19243 | 0.097416 | 0.10415 | L-Alanine L-Arginine L-Asparagine L-Cysteine L-Proline |
| Alanine, aspartate, and glutamate metabolism | 24 | 0.35949 | 3 | 0.004792 | 5.3407 | 0.3786 | 0.11482 | 0.04 | Fumaric acid L-Alanine L-Asparagine |
| Taurine and hypotaurine metabolism | 8 | 0.11983 | 2 | 0.00567 | 5.1726 | 0.44225 | 0.11482 | 0.5 | L-Cysteine Taurine |
| Pantothenate and CoA biosynthesis | 15 | 0.22468 | 2 | 0.019959 | 3.9141 | 1 | 0.32333 | 0.07692 | L-Cysteine Uracil |
Holm: Holm-Bonferroni method; FDR: false discovery rate.